During the most recent week of data available (September 3-9), the U.S. reported about 20,500 new COVID-19 patients admitted to hospitals, according to the CDC. This amounts to:
An average of 2,900 new admissions each day
6.3 total admissions for every 100,000 Americans
8% more new admissions than the prior week (August 27-September 2)
Additionally, the U.S. reported:
12.5% of tests in the CDC’s surveillance network came back positive
A 5% lower concentration of SARS-CoV-2 in wastewater than last week (as of September 13, per Biobot’s dashboard)
25% of new cases are caused by Omicron EG.5, 24% by XBB.1.6, 14% by FL.1.5.1 (as of September 16)
The COVID-19 plateau that I’ve described over the last couple of weeks continues, with wastewater and test positivity data showing that viral spread has slowed in much of the U.S. However, this is likely just a lull before respiratory virus season starts in earnest.
National wastewater data from the WastewaterSCAN project suggest that COVID-19 spread has leveled off in recent weeks, after rising throughout July and August. Biobot Analytics’ data present a similar picture, though the company didn’t update its data this past Thursday (so the most recent numbers are as of September 13).
SCAN and Biobot’s data both show plateaus or declines in all four major regions. But the Northeast and Midwest are reporting more coronavirus in their wastewater sites (at least, in aggregate) than the South and West Coast.
Some sewersheds in the Northeast and Midwest regions have reported increases in recent weeks, while others are leveling off. In Bostonand New York City, for example, most sewersheds report declines or plateaus; while sewersheds in Kansas City and Lawrence, Kansas report upward trends.
To find wastewater data for your region, check the Biobot, WastewaterSCAN, and CDC dashboards. I maintain a list of national, state, and a few local wastewater surveillance dashboards on the COVID-19 Data Dispatch website.
National COVID-19 test positivity is also trending slightly down, according to the CDC’s surveillance network. Test positivity fell slightly to 12.5% in the week ending September 16, from over 14% in the prior three weeks. Walgreens’ testing data show a continued decline in positivity as well.
Hospital admissions for COVID-19 are still going up, according to the CDC—though these data are reported with a significant delay. More than 20,000 people were hospitalized with COVID-19 during the week ending September 9, demonstrating that this disease can still cause severe symptoms. And the CDC has no surveillance data on Long COVID, making that similarly-harmful outcome less visible.
It’s now officially fall, and October marks the start of the respiratory virus season—meaning we can expect more spread of the flu, RSV, and other pathogens along with COVID-19. This is a good time to stock up on high-quality masks, air filters, and other tools that help protect against multiple diseases.
During the most recent week of data available (August 20-26), the U.S. reported about 17,400 new COVID-19 patients admitted to hospitals, according to the CDC. This amounts to:
An average of 2,500 new admissions each day
5.3 total admissions for every 100,000 Americans
16% more new admissions than the prior week (August 13-19)
Additionally, the U.S. reported:
13.5% of tests in the CDC’s surveillance network came back positive
A 0.3% higher concentration of SARS-CoV-2 in wastewater than last week (as of September 6, per Biobot’s dashboard)
23% of new cases are caused by Omicron XBB.1.6; 22% by EG.5; 15% by FL.1.5.1 (as of September 2)
After two months of consistent increases in major COVID-19 metrics, we have once again reached, “Has the surge peaked?” territory. Preliminary data from wastewater and testing are suggesting potential plateaus, while more people are still getting hospitalized with COVID-19.
National trends from Biobot Analytics’ wastewater surveillance network show very similar coronavirus levels in sewage this week and last week: 641 virus copies per milliliter of sewage on September 6, compared to 639 on August 30. These data are preliminary, though, and could change as more sewersheds report.
Biobot’s regional data suggest different trends in different parts of the country: the South and West coast might be turning around, the Northeast is still reporting an increase (but the speed of increase there is slowing), and the Midwest is reporting a sharp increase following a recent decrease.
Data from the CDC networkand WastewaterSCAN similarly show mixed results depending on your location. Among CDC sites with recent data, about half reported increased coronavirus in their wastewater in the last two weeks, while the other half reported decreases. WastewaterSCAN’s network reports continued increases in Midwestern states, including sewersheds in Michigan, Ohio, and Kansas.
Test positivity data from the CDC’s respiratory surveillance network also indicate that the summer surge might have peaked, or at least might be slowing. For the first time in several weeks, test positivity decreased slightly in the most recent CDC update, from 14.1% in the week ending August 26 to 13.5% in the week ending September 2.
Walgreens’ COVID-19 positivity tracker (which shares data from tests conducted by the pharmacy network) reported a slight decrease as well, from 43.6% in the week ending August 26 to 40.6% in the week ending September 2. Like the wastewater surveillance data, this information is preliminary but could be a good sign.
Meanwhile, COVID-19 hospitalizations—a more delayed metric—are still increasing. About 2,500 people were newly hospitalized with COVID-19 each day in the week ending August 26. Hospitalizations have particularly gone up for older adults, according to data from insurance company Humana shared with STAT News.
Many students went back to school last week, as the fall semester gets underway. This could be another driver of COVID-19 spread, as travel and gatherings were in the summer. Better air quality, masks, and other measures could make schools safer for students, teachers, staff, and their families.
During the most recent week of data available (August 13-19), the U.S. reported about 15,100 new COVID-19 patients admitted to hospitals, according to the CDC. This amounts to:
An average of 2,200 new admissions each day
4.6 total admissions for every 100,000 Americans
19% more new admissions than the prior week (August 6-12)
Additionally, the U.S. reported:
14.9% of tests in the CDC’s surveillance network came back positive
A 3% higher concentration of SARS-CoV-2 in wastewater than last week (as of August 30, per Biobot’s dashboard)
23% of new cases are caused by Omicron XBB.1.6; 22% by EG.5; 15% by FL.1.5.1 (as of September 2)
The late-summer COVID-19 surge is still in full swing, with all major metrics showing further increases in disease spread this week. BA.2.86 isn’t spreading widely yet but is worth continued surveillance.
Last week, I wrote that wastewater data from Biobot Analytics showed a potential plateau—but cautioned those data were tentative. Unfortunately, further updates this week suggest that COVID-19 transmission is still increasing, albeit not as dramatically as it was in July.
Data from WastewaterSCAN show a similar pattern: a sharp increase in COVID-19 spread from late June through July, followed by a slight leveling off, and then followed by further increase. This could be caused by a newer variant entering the picture, driven by behaviors, or (most likely) some combination of the two.
Regional data from both Biobot and WastewaterSCAN indicate that COVID-19 transmission might be approaching plateaus in the South and Midwest, but is going up sharply in the Northeast and West coast. The Midwest, after showing decreases in Biobot’s data over recent weeks, is now trending up again.
The CDC’s test positivity and hospitalization numbers continue to rise as well. New hospital admissions for COVID-19 reached 2,000 per day during the week ending August 19, and are likely still higher now. Test positivity is up to 15%, the highest this metric has been since last winter’s holiday surge.
In the CDC’s latest variant estimates (posted on Saturday), EG.5 and XBB.1.6 continue to dominate in a crowded landscape of Omicron XBB relatives. The agency hasn’t yet found enough BA.2.86 for this new variant to be included in the update. However, this could indicate low testing rather than an actual low prevalence of BA.2.86.
The CDC often takes COVID-19 reporting breaks over holiday weekends, and this one is no exception: the agency will not update its dashboard on Monday, according to a note posted at the top of the page. Hospitalizations, test positivity, and other metrics will be updated later in the week.
Of course, the coronavirus doesn’t care about holidays—in fact, it usually spreads more widely when people travel and gather. Fully understanding this Labor Day weekend’s impact could take several weeks, at our current pace of data reporting.
COVID-19 is spreading more in all regions of the country, according to Biobot’s data. Data as of July 27, based on samples collected the week of July 24.
During the most recent week of data available (July 9 through 15), the U.S. reported about 7,100 new COVID-19 patients admitted to hospitals, according to the CDC. This amounts to:
An average of 1,000 new admissions each day
2.2 total admissions for every 100,000 Americans
10% more new admissions than the prior week (July 2-8)
Additionally, the U.S. reported:
7.6% of tests in the CDC’s surveillance network came back positive
A 17% higher concentration of SARS-CoV-2 in wastewater than last week (as of July 26, per Biobot’s dashboard)
24% of new cases are caused by Omicron XBB.1.6; 19% by XBB.1.9; 13% by XBB.2.3 (as of July 22)
Several major metrics continue to point to a summer increase in COVID-19 spread. Coronavirus levels in wastewater are up in all major regions, as is test positivity from the CDC’s network. Hospitalizations have started ticking up as well.
Nationally, coronavirus levels in wastewater have doubled in the last month, according to Biobot Analytics. Viral levels are on par with this period in summer 2021, at the start of that year’s Delta surge, and are the highest they’ve been since this year’s holiday surge concluded.
Data from the WastewaterSCAN network similarly shows COVID-19 upticks in the last month, though the team’s latest national update notes that current levels are still low compared to the start of 2023. WastewaterSCAN recently added national wastewater levels to its dashboard, making it easier to track broad trends from this sewage testing network.
Test positivity data from the CDC’s respiratory lab network are still increasing as well. National test positivity was 7.6% in the week ending July 22, compared to 4.5% about a month ago, an increase of about 70%.
The CDC’s hospitalization data are also showing an increase now: new COVID-19 patients admitted to hospitals went up by about 10% from the week ending July 8 to the week ending July 15. These are the most recent hospitalization numbers available, as the CDC is still reporting this metric with a delay.
Wastewater and positivity data suggest that COVID-19 spread is increasing in all major regions of the country. All regions are also dealing with the virus’ continued evolution, as a variety of XBB lineages circulate and compete with each other.
Several national publications reported on these COVID-19 increases in the last week, pointing to the potential for a summer surge. I personally liked this article from Dylan Scott at Vox, which also covers implications for COVID-19 this winter.
But the COVID-19 Data Dispatch was on this potential surge weeks before any mainstream media news site. If you appreciate our early warnings, please donate to support this work!
According to wastewater data from Biobot, COVID-19 spread right now is lower than at this time last year, but higher than the prior two years.
In the past week (May 7 through 13), the U.S. reported about 9,200 new COVID-19 patients admitted to hospitals, according to the CDC. This amounts to:
An average of 1,300 new admissions each day
2.8 total admissions for every 100,000 Americans
5% fewer new admissions than last week (April 30-May 6)
Additionally, the U.S. reported:
A 4% lower concentration of SARS-CoV-2 in wastewater than last week (as of May 17, per Biobot’s dashboard)
64% of new cases are caused by Omicron XBB.1.5; 13% by XBB.1.9; 14% by XBB.1.16 (as of May 13)
An average of 75,000 vaccinations per day
Nationwide, COVID-19 spread in the U.S. continues to be in a somewhat-middling plateau: lower than the massive amount of Omicron transmission we all got used to throughout late 2022, but still higher than the lulls between outbreaks we saw in prior years.
Biobot’s national wastewater surveillance offers a helpful visual for this comparison. As of May 20, the company calculates a national average of 221 viral copies per milliliter of sewage (a common unit for quantifying SARS-CoV-2 in wastewater), based on hundreds of sewage testing sites in its network.
In late May of last year, when early Omicron offshoots were spreading widely, this value was several times higher: 736 viral copies per milliliter. But around the same time in 2021 (when millions of Americans were getting their first vaccine shots) or 2020 (when the very first big surge had ended), wastewater concentrations were under 100 viral copies per milliliter.
It’s also important to note that wastewater concentrations have been fairly level for a couple of months now, both nationally and for all four major regions. High immunity across the population and a lack of divergent new variants have kept us from seeing a new surge since the 2022 winter holidays; but without widespread safety measures, I suspect we’re unlikely to see a drop in transmission below the current baseline.
Hospital admissions, now the CDC’s primary metric for tracking this disease, show a similar picture to the wastewater data. Numbers are low and ticking ever-so-slightly downward, but they’re not zero: about 1,300 people were admitted to hospitals with COVID-19 each day in the week ending May 13.
Deaths with COVID-19 also remain at low yet significant numbers. While the CDC reports only 281 deaths in the last week, this information is now presented with a greater delay than during the federal public health emergency, as the agency had to switch from death reports received directly from states to death certificate data. For the week ending May 6, the CDC revised its number up from about 300 to 622 COVID-19 deaths.
There are no changes to variant estimates this week, as the CDC is now updating that data every other week rather than weekly. XBB.1.5 remains the dominant variant, with XBB.1.16 and XBB.1.19 slowly gaining ground.
Overall, it’s getting harder to identify detailed COVID-19 trends, but a lot of data still do remain available. I’ll keep providing updates as best I can.
Second Omicron boosters for high-risk adults: The FDA and CDC are planning to authorize a second round of bivalent, Omicron-specific vaccines for high-risk adults, the Washington Post reported this week. This decision will apply to Americans over age 65 and those who have compromised immune systems, with these groups becoming eligible four months after their initial bivalent boosters. It’s unclear exactly when the decision will become official; the FDA and CDC will make authorizations sometime “in the next few weeks,” according to WaPo.
HHS announces (underwhelming) Long COVID progress: This week marks one year since Biden issued a presidential memo kicking off a “whole-of-government response” to Long COVID. The Department of Health and Human Services (HHS) commemorated the occasion with a fact sheet sharing the federal government’s progress so far. Unfortunately, that progress has been fairly minor, mostly consisting of reports and guidance that largely summarize existing government programs or build on existing systems (such as Veterans Affairs hospitals). Many of the Long COVID programs that Biden previously proposed have not received funding from Congress; meanwhile, the National Institutes of Health’s RECOVER initiative, the one program that has been funded, has faced a lot of criticism.
RECOVER PIs recommend action on treatment: Speaking of RECOVER: this week, a group of scientists leading research hubs within the national study called for federal funding that would support treatment. The principal investigators (PIs) of these hubs have developed expertise in Long COVID through recruiting and studying patients, leading them to identify gaps in available medical care for long-haulers. To respond, the PIs recommend that Congress allocate $37.5 million to support Long COVID medical care at the RECOVER research sites. Their proposed budget includes patient outreach, telehealth support, educating healthcare workers on Long COVID, and more.
Ventilation improvements in K-12 schools: The CDC released a new study this week in its Morbidity and Mortality Weekly Report, sharing results of a survey (conducted last fall) including about 8,400 school districts representing 62% of public school students in the U.S. Research company MCH Strategic Data asked the districts about how they’d improved ventilation in their school buildings, along with other COVID-19 safety measures. About half of the districts reported “maintaining continuous airflow in classrooms,” one-third reported HVAC improvements, 28% reported using HEPA filters, and 8% reported using UV disinfectants. The results indicate that many districts have a long way to go in upgrading their indoor air quality.
Flu vs. COVID-19 mortality risk: Ziyad Al-Aly and his colleagues at the VA healthcare system in St. Louis have published another paper analyzing COVID-19 through the VA’s electronic health records. This study, published in JAMA Network, describes the mortality risk of COVID-19 compared to seasonal flu for patients hospitalized during the 2022-2023 winter season. The researchers evaluated about 9,000 COVID-19 patients and 2,400 flu patients, finding that risk of death for COVID-19 patients in the 30 days following hospitalization was about 1.6 times as high as the risk of death for flu patients. Despite great advances in vaccines and treatments, COVID-19 remains more dangerous than other seasonal viruses, the study suggests.
Biobot launches mpox dashboard: This week, leading wastewater surveillance company Biobot Analytics launched a new dashboard displaying its mpox (formerly monkeypox) monitoring. Biobot tests for mpox at hundreds of sewage sites across the U.S., largely through its partnership with the CDC, and will continue this monitoring through at least summer 2023. The new dashboard shows mpox detections nationally over time and monitoring sites by state; it also includes some information on how mpox surveillance differs from COVID-19 surveillance.
My attempt to explain the wastewater surveillance funding ecosystem in one diagram. (Credit: Betsy Ladyzhets)
This week, I have a new story out in Scientific American about why the wastewater surveillance infrastructure built during the pandemic may not last in the long term. While current monitoring projects aren’t likely to go anywhere right now, issues with funding, uneven commitments at state and local levels, and the overall novelty of this field may lead those programs to shut down in the coming years.
Here’s the story’s opening paragraphs:
During the past three years of the pandemic, testing sewage water for the virus that causes COVID has become a valuable tool: it has spotted surging infections and new variants weeks before they showed up in medical clinics, for instance. The technology has also warned of other health threats such as seasonal viruses and increased opioid use.
But now its long-term ability to protect public health is in jeopardy. Funding uncertainty from the federal government and uneven commitments from state health departments have raised the specter that wastewater monitoring programs may shut down in the future.
The U.S. Centers for Disease Control and Prevention’s National Wastewater Surveillance System (NWSS), which includes the majority of wastewater testing sites in the U.S., is “fully funded through 2025,” says Amy Kirby, director of the program. But after that, “new sources of sustainable funding” are needed, Kirby says, ideally through the CDC’s regular budget rather than resources tied to COVID. Uncertainty about money—along with logistical challenges and questions about how to interpret data from this relatively novel source—has made some state governments hesitant to invest in the technology, leading to an uneven national system.
My reporting for this piece involved interviews with the CDC, state and local public health agencies, and other major wastewater organizations (Biobot, WastewaterSCAN). I learned a lot about the overall ecosystem for funding wastewater surveillance, including a lot of somewhat-technical details that didn’t make it into the SciAm story. So, I’m sharing some of those details here.
Where wastewater surveillance funding comes from:
The primary funder for wastewater monitoring programs across the U.S. is CDC NWSS. The CDC itself received funding through the American Rescue Plan in 2021, sufficient to fully fund NWSS through 2025.
That CDC funding has gone in two main directions. First, the CDC has funded state and local public health agencies to set up (and maintain) their own wastewater testing projects. This is how most of the states with robust programs (places like New York, Utah, Virginia, Ohio) have funded their efforts. State and local health agencies may also receive funding from their own local governments, though most of the agencies I talked to for my story said they were primarily relying on the CDC. New York State is one major example of a state government funding wastewater surveillance right now.
And second, the CDC has set up national contracts with wastewater testing companies to supplement NWSS in places where monitoring otherwise might not be happening. The agency first contracted with LuminUltra in early 2022, then switched to Biobot Analytics last spring. Earlier this year, Biobot’s contract with the CDC was extended for six months, through July. After that, the agency plans to enter a new, five-year contract with a wastewater testing company that will cover COVID-19 as well as other emerging diseases, like mpox. This contract could go to Biobot or another company; the CDC is currently going through an application process.
Biobot and other private companies like it are also receiving funding from private sources, such as venture capital firms. In addition, individual water treatment facilities, local governments, and even businesses might set up contracts with private companies to help them test the wastewater in their jurisdiction. For example, Toronto’s Pearson Airport has contracted with LuminUltra to test wastewater from the airport terminals. In these cases, funding is coming from the specific organization that wants testing, rather than a larger program. Biobot also tests at hundreds of sites for free through its Biobot Network, in exchange for sharing the data publicly.
Finally, there’s a whole separate ecosystem of academic wastewater surveillance efforts, mostly run by university labs or research centers. WastewaterSCAN is the biggest example of this right now; the project was founded at Stanford and Emory Universities, but has since expanded through grants and philanthropic funding to cover about 150 sites across the country. Most academic projects either partner with specific treatment facilities in their areas or test the sewage on their campuses—SCAN is an exception with its broader scale.
Concerns for wastewater surveillance’s long-term future:
As you can probably tell by this description of the funding landscape, wastewater surveillance in the U.S. is pretty complicated. When scientists started testing wastewater for SARS-CoV-2 in spring 2020, this was basically a grassroots effort with different research projects across the country trying out different things. CDC NWSS has worked hard to compile data into one national system and develop standards, but the system is still far from unified.
For the CDC program to continue its efforts, the agency needs more long-term funding—and this funding shouldn’t be tied to COVID-19. The potential for wastewater surveillance to inform public health decisions goes far beyond this pandemic, and funding should reflect that potential; also, no COVID-specific funding packages have passed Congress since the American Rescue Plan, in 2021.
One way Congress could do this would be by expanding a funding system called “Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases,” or ELC. Most wastewater grants to state and local health agencies over the last couple of years have gone through ELC, though the funding came from the American Rescue Plan. Many of the health officials I talked to for my story like ELC, know how to fill out the annual applications, and would want to keep using it to receive wastewater funding.
Before the pandemic, the ELC program was drastically underfunded, I learned from experts at the Association of Public Health Laboratories (APHL). States’ applications historically “vastly exceed the money that CDC is given to put out for them,” APHL policy officer Peter Kyriacopoulos told me. APHL recommends that Congress should expand the program’s funding from $300 million per year (its pre-pandemic benchmark) to $800 million per year, or more. The ELC program is up for renewal this year, which could be an opportunity for Congress to add more permanent funding for wastewater surveillance and other epidemiological efforts.
More permanent funding could go a long way in convincing more state health agencies to invest in wastewater surveillance programs, rather than relying on outside assistance from companies like Biobot or academic partners. More data and guidance on how to actually use wastewater data to inform public health decisions would help, too, since many agencies are still figuring this out. Such investment at the state level would help make the country’s wastewater infrastructure more comprehensive, and more capable of responding to new health threats.
Instead, right now, we have an uneven system. Some places are regularly monitoring for COVID-19 and easily able to expand to new testing targets, while others might lose this valuable data source in the next year or two. For any local reporters reading this, I highly recommend digging into your community’s wastewater surveillance system, and figuring out whether it’s set up for the long term.
Biobot provides wastewater testing and analysis for more than 400 sites in the NWSS network, accounting for about one-third of the system’s total 1,200 sites. The CDC/Biobot arrangement basically makes it easy for these wastewater treatment plants to participate in COVID-19 and mpox testing, since sites can send in samples without spending the time and resources needed to build up their own testing programs.
I was glad to see this news, as the continued contract will mean no interruptions in CDC NWSS data for at least another six months. Long-time readers might remember that there were major wastewater data gaps last spring, when the CDC switched contractors from LuminUltra to Biobot.
Of course, six months is far from the long-term investment that the U.S. should be making in wastewater surveillance… but that’s a topic for another week.
2022 America’s Health Rankings released: This week, the United Health Foundation released its 2022 edition of America’s Health Rankings, a comprehensive report providing data for more than 80 different health metrics at national and state levels. The 2022 report includes new metrics tailored to show COVID-related disparities; for example, Black and Hispanic Americans had higher rates of losing friends and family members to COVID-19 compared to other groups. I’ve used data from past iterations of this report in stories before, and I’m looking forward to digging into the 2022 edition.
FDA authorizes bivalent boosters for young kids: This week, the FDA revised the emergency use authorizations (EUAs) of both Pfizer’s and Moderna’s updated, Omicron-specific booster shots to include children between six months and five years old. Kids who previously got two shots of Moderna’s vaccine for this age group can receive a bivalent booster two months later, while kids who got two shots of Pfizer’s vaccine can receive a bivalent booster as their third dose. (Remember, Pfizer’s vaccine for this age group includes three doses.) The updated EUAs will help protect young children from Omicron infection, though uptake will likely be low.
CDC updates breakthrough case data: Speaking of the updated boosters: the CDC recently added data on these shots to its analysis of COVID-19 cases and deaths by vaccination status. In September, people who had received a bivalent, Omicron-specific boosters had a 15 times lower risk of dying from COVID-19 compared to unvaccinated people; and in October, bivalent-boosted people had a three times lower risk of testing positive compared to the unvaccinated. The CDC will update these data on a monthly basis.
Director Walensky discusses authority challenges: One bit of coverage from the Milken Future of Health Summit that caught my attention: CDC Director Dr. Rochelle Walensky talked about the agency’s limitations in collecting data from states, reports Rachel Cohrs at STAT News. Walensky specifically highlighted the challenges that the CDC might face in collecting data when the public health emergency for COVID-19 ends, something I’ve previously covered in this publication.
Boston establishes neighborhood-level wastewater testing: Finally, one bit of wastewater surveillance news: the city of Boston is setting up 11 new sites to test wastewater, giving local public health officials more granular information about how COVID-19 is spreading in the region. The new initiative is a partnership with Biobot Analytics, the same wastewater testing company that has long worked with Boston, the CDC, and public health institutions across the country. (Boston was one of the first cities to start doing this testing.) Also, speaking of Biobot: the company just added a nice chart of coronavirus variants in U.S. wastewater over time to its dashboard.
As we head into the holidays with limited COVID-19 testing and undercounted case numbers, wastewater surveillance is the best way to evaluate how much the virus is spreading in your region. And it’s now available in more places than ever, thanks to the many research groups and public health agencies setting up sewage testing.
Let’s review the options. First, there are now three national dashboards with U.S. wastewater data, each covering a different set of locations.
The CDC’s National Wastewater Surveillance System is the biggest, including more than 1,000 sites from almost every state, though some states have far better coverage than others. Click on an individual site to see coronavirus trends for that location.
Biobot Analytics is the biggest private company doing wastewater surveillance; it provides analysis for hundreds of sites in the CDC NWSS network as well as its own, separate network. Biobot’s national and regional data (which include NWSS sites) are particularly helpful for large-scale trends.
WastewaterSCAN is a project that started from an academic partnership between Stanford University, Emory University, the University of Michigan, and communities in California. It’s since expanded to include sites in about 20 states, and participating sewersheds are tested for monkeypox, flu, and RSV in addition to the coronavirus.
Second, 21 states currently have their own wastewater dashboards or reporting systems. If this is available in your area, I highly recommend looking at your local dashboard in addition to the national options. State and local dashboards tend to include more detailed and/or more frequently updated data, and are often tailored to their community’s needs more closely.
These are the states with wastewater dashboards; see the resource page for links and more info:
California, Colorado, Georgia, Hawaii, Idaho, Indiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, New York State, North Carolina, Ohio, Oklahoma, Oregon, Utah, West Virginia, Wisconsin.
Wastewater trends do not correspond directly to infection trends, because people sick with COVID-19 might shed the virus at different rates (based on where they are in their infection, variants, and other factors). Some researchers are working to better understand the correlation between wastewater trends and cases, but for now, the sewage data are best understood as a broad indicator of risk—not a precise estimate of how many people in your community are sick.
COVID-19 Data Dispatch 